Nation's Largest Pancreatic Cancer Early Detection Study Holds Annual Meeting in San Diego

The PRECEDE Study focuses on enhancing early detection in pancreatic cancer, which remains the third leading cause of cancer mortality in the U.S., with a five-year survival rate of merely 13%. The study, which includes the collaboration of 51 pancreatic centers globally, aims to detect pancreatic cancer at its earliest stages, improving survival rates.

Founded in 2020, PRECEDE targets individuals with a family history or genetic predisposition to pancreatic cancer. The consortium's annual meeting in San Diego gathers experts to discuss recent advancements in early detection technologies, including blood tests and AI-based imaging.

The study, headquartered at Moores Cancer Center, UC San Diego Health, offers participation to eligible patients and aims to raise the five-year survival rate to 50% over the next decade. Already, more than 7,000 patients are enrolled in this expansive research initiative.